Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?

Kevin Washetine (1) , Simon Heeke (2) , Christelle Bonnetaud (1) , Mehdi Kara-Borni (1) , Marius Ilié (2, 1) , Sandra Lassalle (2, 1) , Catherine Butori (1) , Elodie Long-Mira (2, 1) , Charles Hugo Marquette (2, 1) , Charlotte Cohen (1) , Jérôme Mouroux (2, 1) , Eric Selva (1) , Virginie Tanga (1) , Coraline Bence (1) , Jean-Marc Félix (1) , Loic Gazoppi (1) , Taycir Skhiri , Emmanuelle Gormally , Pascal Boucher , Bruno Clement (3) , Georges Dagher (4) , Véronique Hofman (2, 1) , Paul Hofman (2, 1)

1 CHU Nice - Centre Hospitalier Universitaire de Nice
2 IRCAN - Institut de Recherche sur le Cancer et le Vieillissement
3 NuMeCan - Nutrition, Métabolismes et Cancer
4 INSERM - Institut National de la Santé et de la Recherche Médicale

Lung cancer is the major cause of death from cancer in the world and its incidence is increasing in women. Despite the progress made in developing immunotherapies and therapies targeting genomic alterations, improvement in the survival rate of advanced stages or metastatic patients remains low. Thus, urgent development of effective therapeutic molecules is needed. The discovery of novel therapeutic targets and their validation requires high quality biological material and associated clinical data. With this aim, we established a biobank dedicated to lung cancers. We describe here our strategy and the indicators used and, through an overall assessment, present the strengths, weaknesses, opportunities and associated risks of this biobank.

Keywords: sustainability; quality; efficiency; indicators; lung tumor biobank

Domains: Life Sciences [q-bio]

Kevin Washetine, Simon Heeke, Christelle Bonnetaud, Mehdi Kara-Borni, Marius Ilié, et al.. Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?. Cancers, 2018, 10 (7), pp.E220. ⟨10.3390/cancers10070220⟩. ⟨hal-01834086⟩